Post on 30-Jan-2021
Do not distribute or reproduce without permission 1 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
LNE/G-MED North America, Inc
MEDDEV 2.7.1 Rev 4:
Implementing New Requirements for
Clinical Evaluation Reports (CER)
Do not distribute or reproduce without permission 2 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Speaker
Anne Le Rouzo
• Sr Lead Auditor ISO 13485, ISO 9001, CMDR, MDD, AO regulations, MDD
• Non active implantable MD specialist at G-MED NA
• Technical Documentation and Design Dossier assessor
LNE / G-MED North America, Inc.
Do not distribute or reproduce without permission 3 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
MEDDEV 2.7.1 rev 4
Do not distribute or reproduce without permission 4 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4
• New Concept introduced:
sufficient clinical evidence
A Quantity and Quality of the clinical evidence
guaranteeing the scientific validity of the conclusions
Do not distribute or reproduce without permission 5 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4
When is clinical evaluation undertaken?
• Clinical evaluation is conducted throughout the life cycle of a medical device, as an ongoing process.
Do not distribute or reproduce without permission 6 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4
Who conducts the clinical evaluation? The clinical evaluation should be conducted by a suitably qualified individual
or a team, taking into consideration:
- Definition of the requirements in terms of qualification in line with the
device and its clinical performance and risks
- Justification of choice of the evaluator(s)
- Declaration of interest of each evaluator
- Technical and scientific knowledge,
- Research methodology, information management, regulatory
requirements, and medical writing knowledge
- Training and experience
Do not distribute or reproduce without permission 7 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4
How is the clinical evaluation performed?
Definition of the performance data and clinical safety data of the device
5 stages from the scoping and clinical evaluation plan to finalization of the CER
Do not distribute or reproduce without permission 8 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 0
Scoping & clinical evaluation plan
Stage 1
Identification of pertinent data
Stage 2
Appraisal of pertinent data
Stage 3
Analysis of clinical data
Stage 4
Clinical Evaluation Report
Do not distribute or reproduce without permission 9 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 0: Definition of the scope of the clinical evaluation & Clinical evaluation plan
Detailed device description Appendix A3 Identification of the devices (models, sizes, software versions,
accessories
Concise physical and chemical description (materials, incorporated medicinal substances, tissues, or blood products), Mechanical and physicochemical characteristics;
Technologies used
Description of innovative aspects of the device
Place of the device in regards to available treatment / management/ diagnostic options.
Exact description of intended purpose, medical indications
Do not distribute or reproduce without permission 10 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 0: Definition of the scope of the clinical evaluation & Clinical evaluation plan
Setting up the clinical evaluation plan: aspects of the plan depending on the stage in the lifecycle of the product: before CE marking vs. CE marked
Device description
Information needed for evaluation of equivalence (pre-CE)
Risk management
Current knowledge/ state of the art in the corresponding medical field
Data sources
Changes(post-CE)
New emerging clinical concerns , PMS aspects (post-CE)
Do not distribute or reproduce without permission 11 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 1: Identification of the pertinent data
Data generated and held by the manufacturer: Pre-market clinical investigations
All clinical data generated from RM activities and the PMS programs
Pre-clinical data
Data from the litterature: Clinical data relevant to the device under evaluation (data relating to
either the device itself or to equivalent device)
Current knowledge/state of the art
Do not distribute or reproduce without permission 12 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 2: Appraisal of pertinent data
Evaluation of data including scientific validity, relevance and their contribution to the demonstration of conformity
– Quality of the methodology & Scientific Validity of the content (9.3.1)
– Relevance of the data (9.3.2)
– Weight contribution of each data
Do not distribute or reproduce without permission 13 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Clinical Equivalence
Revision 3
• Same intended use and clinical conditions • Same site in the body • Similar population (including age, anatomy, physiology) • Similar relevant critical performance according to the clinical effect
expected for a specific intended use
• Same clinical conditions and same intended purpose • Same site in the body • Similar population (including age, gender, anatomy, physiology) • Not foreseen to deliver significantly different performances
Revision 4
Do not distribute or reproduce without permission 14 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Technical Equivalence
Revision 3
• Used under similar conditions of use • Have similar specifications and properties (i.e. tensile strength, viscosity,
surface characteristics…) • Be of similar design • Use similar deployment methods (if applicable) • Have similar principles of operations
• Used under the same conditions of use • Have similar specifications and properties (i.e. tensile strength, viscosity,
intensity of energy, wavelength, porosity, surface texture…) • Use similar deployment methods (if applicable) • Have similar principles of operation and critical performance requirements
Revision 4
Do not distribute or reproduce without permission 15 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Biological Equivalence
Revision 3
• Use same materials in contact with the same human tissues or body fluids
• Use the same materials or substances in contact with the same human
tissues or body fluids Exception: devices in contact with intact skin and minor components of devices.
Revision 4
Do not distribute or reproduce without permission 16 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Assuming Equivalence
Equivalence can only be based on a single device
The three characteristics (clinical, technical, biological) must be fulfilled for this same device
“Similar” means that no clinically significant differences on the performance and safety of the device would be triggered by the differences between the device currently under assessment and the device presented as being equivalent
Do not distribute or reproduce without permission 17 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Assuming Equivalence
All differences to be identified, fully disclosed, and assessed
Comparative engineering drawings or pictures must be presented to be able to compare the design (shape) and the sizes of components in contact with the body
The manufacturer must verify whether the presumed equivalent medical device has been manufactured using a special treatment (e.g. surface modification, a process that changes the characteristics of the material); if this is the case, the treatment could cause differences in the technical and biological characteristics; this should be taken into account for the demonstration of equivalence and documented in the CER
Do not distribute or reproduce without permission 18 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Assuming Equivalence
Comparative plans or images should be included to compare the shapes and sizes of the elements in contact with the body
The manufacturer should include the non-clinical information (e.g. pre-clinical testing reports) in the technical documentation and summarize the information in the CER (with pointer to relevant sections of the technical documentation)
For the evaluation of technical characteristics, devices that achieve the same therapeutic result by a different means cannot be considered equivalent
Do not distribute or reproduce without permission 19 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Assuming Equivalence
For the evaluation of the biological characteristics: – when a detailed chemical characterization of the materials that are in contact with
the body is necessary, then ISO 10993-18 Appendix C can be used to show the toxicological equivalence, but this is just part of the evaluation of the biological criteria;
– sourcing and manufacturing procedures may adversely affect impurity profiles repetition of testing when production methods or sourcing are changed;
– it may be necessary to show histopathological studies to demonstrate that the same host response is obtained in vivo for the application and the planned duration of contact;
– for the tests on animals, the differences between species can reduce the predictive value of the test; the choice of the test and its predictive value must be justified
Do not distribute or reproduce without permission 20 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Assuming Equivalence
The only clinical data considered relevant are the data obtained when the equivalent device is a CE marked medical device used for its intended purpose as stated in the IFU.
Exceptions may be considered. When the equivalent device is not a CE marked device, information on the regulatory status of the equivalent device and a justification for the use of its data should be included in the clinical evaluation report. The justification should explain if the clinical data are transferable to the European population, and an analysis of possible gaps for good clinical practice (e.g. ISO 14155) and the relevant harmonized standards.
Do not distribute or reproduce without permission 21 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 3: Analysis of the clinical data
Analysis the data, whereby conclusions are reached about:
Compliance with the essential requirements in terms of performance and safety, including the ratio benefit / risk
The contents of the supporting documents
Residual risks and uncertainties or Questions unanswered (including rare complications, long-term performance, safety during use in "real life"), if these are acceptable for CE marking, it is necessary that they are followed up by PMS
Do not distribute or reproduce without permission 22 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Stage 4: Clinical Evaluation Report
Compilation of relevant clinical data, to establish sufficient clinical evidence necessary to demonstrate compliance.
Outlines all stages of the clinical evaluation: Stage 0, scope of he clinical evaluation
Stage 1, identification of pertinent data
Stage 2, appraisal of pertinent data
Stage 3, analysis of the clinical data
CER: approved, dated – Controlled document (QS)
CV and declaration of interests
Do not distribute or reproduce without permission 23 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4: Active update of the CER – When ? Frequency defined and justified, based on criteria (risk,
innovation, changes)
If new information coming from the PMS, potentially impacting the current evaluation
If no new information is coming from the PMS:
• At least annually if the DM is at risk and / or innovative
• Every 2 to 5 years, if the DM is not at risk and / or innovative, with justification
Do not distribute or reproduce without permission 24 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
The new developments of MEDDEV 2.7.1 rev 4: Active update of the CER – Why ? Ratio benefit/risk profile, side effects and risk mitigation
measures: Confirmation of Safety and acceptance per current state of the art
Accuracy/relevance of device information materials
Accuracy of PMS plan
Confirmation of existing claims
Justification of new claims
Do not distribute or reproduce without permission 25 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
Clinical Evaluation - Sufficient clinical evidence to meet
ERs? - Significance of any clinical risks after
risk control?
Risk Management - Are all clinical risks in RMR?
- Risk control identified and verified? - Benefit/Risk ration justified?
Post-Market Surveillance - Define the PMS Plan based on the
subtle and long term effects to be investigated
- Is PMCF study needed as part of the PMS plan?
Information Materials - Is the IFUs accurate?
- Si all the safety information displayed in IFUs reflected in the RMR?
Do not distribute or reproduce without permission 26 1/25/2017
contact@lne-america.com 1-301-495-0477 lne-america.com
LNE / G-MED North America, Inc.
3930 Knowles Ave. Suite 306 Kensington, Maryland 20895
Office: (301) 495-0477 E-mail : contact@lne-america.com
Thank you!
mailto:contact@lne-america.commailto:contact@lne-america.commailto:contact@lne-america.com